MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma MAGNETISMM-4

What's the purpose of this trial?

The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.

This trial is currently open and accepting patients.

What will happen during the trial?

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

Inclusion Criteria:

  • Relapsed/refractory multiple myeloma with at least 3 prior lines of therapy
  • Refractory to at least one IMiD, one proteasome inhibitor, and one anti-CD38 antibody
  • Measurable disease defined by at least one of the following:
    • Serum M-protein >/= 0.5 g/dL by SPEP
    • Urinary M-protein excretion >/= 200 mg/24 hours by UPEP
    • Serum immunoglobulin FLC >/= 10 mg/dL (>/= 100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio
  • ECOG performance status 0 -1
  • Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade </= 1

Exclusion Criteria:

  • Active plasma cell leukemia
  • Amyloidosis
  • Stem cell transplant with 12 weeks prior to enrollment, or active GVHD
  • POEMS syndrome
  • Any active uncontrolled bacterial, fungal, or viral infection
  • Impaired cardiovascular function or clinically significant cardiovascular diseases within 6 months prior to enrollment
  • Previous treatment with an anti-BCMA bispecific antibody
  • Previous administration with an investigational drug within 30 days or 5 half-lives preceding the first dose of study treatment (whichever is longer)

Additional Trial Information

Phase 1/2

Enrollment: 370 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.


Sylvester Comprehensive Cancer Center University of Miami Health System

Miami, FL

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

SparkCures is working closely with Pfizer to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors